J H Frederik Falkenburg Selected Research

HLA-DP Antigens (HLA-DP)

1/2022	Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity.
1/2021	Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM.
1/2020	Priming of Allo-HLA-DP-Specific Reactivity from the Naïve T Cell Compartment Is Not Exclusively Mediated by Professional Antigen-Presenting Cells.
1/2019	The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells.
9/2013	HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
1/2013	Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J H Frederik Falkenburg Research Topics

Disease

54	Neoplasms (Cancer) 01/2022 - 09/2003
42	Leukemia 01/2022 - 01/2002
40	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 04/2002
26	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2003
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 03/2002
9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2014 - 04/2002
8	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 03/2002
8	Multiple Myeloma 01/2022 - 03/2003
4	Virus Diseases (Viral Diseases) 01/2020 - 04/2011
3	Lymphoma (Lymphomas) 11/2016 - 07/2005
3	Aspergillosis 07/2014 - 04/2011
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2016 - 01/2016
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2014 - 07/2006
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2014 - 01/2011
2	Myeloid Leukemia (Leukemia, Myelocytic) 07/2012 - 08/2011
2	Melanoma (Melanoma, Malignant) 09/2011 - 05/2006
1	Carcinoma (Carcinomatosis) 01/2022
1	Hematologic Diseases (Blood Diseases) 01/2020
1	Disease Progression 01/2020
1	idiopathic Aplastic anemia 10/2017
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2017
1	B-Cell Leukemia (Leukemia, B Cell) 11/2016
1	Testicular Neoplasms (Testicular Cancer) 01/2016
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2016
1	Neutropenia 07/2014
1	Chronic-Phase Myeloid Leukemia (Leukemia, Myeloid, Chronic Phase) 08/2013
1	Blast Crisis (Blast Phase) 06/2013
1	Philadelphia Chromosome 01/2013
1	Carcinogenesis 01/2013
1	B-Cell Lymphoma (Lymphoma, B Cell) 07/2012
1	Aplastic Anemia (Anemia, Hypoplastic) 11/2011
1	Wilms Tumor (Wilm's Tumor) 09/2011
1	Mycoses (Diseases, Fungus) 04/2011
1	Neoplasm Metastasis (Metastasis) 01/2011
1	Adenoviridae Infections (Adenovirus Infections) 11/2010

Drug/Important Bio-Agent (IBA)

28	Minor Histocompatibility AntigensIBA 01/2020 - 04/2002
27	AntigensIBA 01/2022 - 01/2003
15	Peptides (Polypeptides)IBA 01/2022 - 09/2004
15	16-iodo-3-methylhexadecanoic acid (MIHA)IBA 01/2020 - 07/2009
9	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 09/2004
6	HLA-A Antigens (HLA-A)IBA 01/2022 - 09/2004
6	CytokinesIBA 01/2022 - 12/2005
6	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 03/2002
6	HLA-DP Antigens (HLA-DP)IBA 01/2022 - 01/2013
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2003
5	Monoclonal AntibodiesIBA 01/2017 - 02/2015
4	Chimeric Antigen ReceptorsIBA 01/2022 - 02/2015
3	HLA-B*07 antigenIBA 01/2022 - 11/2016
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2017
3	Alemtuzumab (Campath)FDA Link 01/2021 - 01/2018
3	AntibodiesIBA 01/2017 - 08/2011
3	InterferonsIBA 07/2014 - 03/2002
3	LigandsIBA 05/2014 - 08/2011
2	HLA-DPB1 antigen (HLA DPB1)IBA 01/2018 - 09/2010
2	Complement System Proteins (Complement)IBA 01/2017 - 03/2002
2	Biological ProductsIBA 05/2015 - 04/2011
2	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2013 - 07/2006
2	EpitopesIBA 11/2010 - 05/2006
2	Messenger RNA (mRNA)IBA 07/2009 - 05/2006
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2009 - 06/2006
2	Interferon-alpha (Interferon Alfa)IBA 06/2004 - 03/2004
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2022
1	CD20 AntigensIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2020
1	AutoantigensIBA 01/2020
1	CD52 AntigenIBA 12/2019
1	NucleophosminIBA 01/2019
1	1,3- dihydro- 1- (1- ((4- (6- phenyl- 1H- imidazo(4,5- g)quinoxalin- 7- yl)phenyl)methyl)- 4- piperidinyl)- 2H- benzimidazol- 2- oneIBA 01/2018
1	Blocking AntibodiesIBA 01/2018
1	Untranslated Regions (Untranslated Region)IBA 01/2018
1	ipatasertibIBA 01/2018
1	3' Untranslated Regions (3' UTR)IBA 01/2018
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 10/2017
1	Complement Inactivating AgentsIBA 01/2017
1	VaccinesIBA 01/2017
1	Decitabine FDA Link 01/2016
1	fludarabineIBA 01/2016
1	navitoclaxIBA 04/2015
1	venetoclaxIBA 04/2015
1	Imatinib Mesylate (Gleevec)FDA Link 08/2013
1	DNA (Deoxyribonucleic Acid)IBA 02/2013
1	bcr-abl Fusion ProteinsIBA 01/2013
1	HLA-B Antigens (HLA-B)IBA 08/2012
1	thymoglobulin FDA Link 11/2011
1	WT1 ProteinsIBA 09/2011
1	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2011
1	RNA Splice SitesIBA 01/2011

Therapy/Procedure

55	Stem Cell Transplantation 01/2022 - 01/2002
20	Immunotherapy 11/2021 - 07/2002
14	Therapeutics 01/2022 - 05/2006
8	Transplantation 01/2021 - 04/2002
8	Hematopoietic Stem Cell Transplantation 01/2018 - 06/2006
3	Aftercare (After-Treatment) 10/2017 - 06/2013
2	Drug Therapy (Chemotherapy) 03/2009 - 02/2004
2	Homologous Transplantation 09/2003 - 07/2002
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022
1	Induction Chemotherapy 11/2021
1	Donor Selection 01/2020
1	Ligation 01/2018
1	Cell Transplantation 01/2016